These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 37591632)

  • 21. Genetically Programmable Vesicles for Enhancing CAR-T Therapy against Solid Tumors.
    Li X; Zhu T; Wang R; Chen J; Tang L; Huo W; Huang X; Cao Q
    Adv Mater; 2023 May; 35(19):e2211138. PubMed ID: 36814099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
    McKenna MK; Ozcan A; Brenner D; Watanabe N; Legendre M; Thomas DG; Ashwood C; Cummings RD; Bonifant C; Markovitz DM; Brenner MK
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
    Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.
    Zhang Z; Liu C; Wang M; Sun R; Yang Z; Hua Z; Wu Y; Wu M; Wang H; Qiu W; Yin H; Yang M
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models.
    Qin D; Li D; Zhang B; Chen Y; Liao X; Li X; Alexander PB; Wang Y; Li QJ
    Oncoimmunology; 2020 Aug; 9(1):1806009. PubMed ID: 32923168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
    Hickman TL; Choi E; Whiteman KR; Muralidharan S; Pai T; Johnson T; Parikh A; Friedman T; Gilbert M; Shen B; Barron L; McGinness KE; Ettenberg SA; Motz GT; Weiss GJ; Jensen-Smith A
    PLoS One; 2022; 17(5):e0266980. PubMed ID: 35507536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
    Das S; Valton J; Duchateau P; Poirot L
    Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.
    Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W
    Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody.
    Cheng K; Feng X; Chai Z; Wang Z; Liu Z; Yan Z; Wang Y; Zhang S
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability.
    Tang J; Sheng J; Zhang Q; Ji Y; Wang X; Zhang J; Wu J; Song J; Bai X; Liang T
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36849200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
    Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy.
    Zhang Z; Wang G; Zhong K; Chen Y; Yang N; Lu Q; Yuan B; Wang Z; Li H; Guo L; Zhang R; Wu Z; Zheng M; Zhao S; Tang X; Shao B; Tong A
    J Transl Med; 2023 Jan; 21(1):23. PubMed ID: 36635683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment.
    Guo F; Das JK; Kobayashi KS; Qin QM; A Ficht T; Alaniz RC; Song J; Figueiredo P
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34987022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors.
    Liang S; Zheng R; Zuo B; Li J; Wang Y; Han Y; Dong H; Zhao X; Zhang Y; Wang P; Meng R; Jia L; Yang A; Yan B
    Cell Mol Immunol; 2024 Mar; 21(3):213-226. PubMed ID: 38177245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
    Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
    J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.